Novo Nordisk to create the world's first all-diabetes professional cycling team

Novo NordiskNovo Nordisk announced a unique partnership to form Team Novo Nordisk, a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team.

Team Novo Nordisk will use life experiences and competitiveness to motivate people affected by diabetes. Throughout 2013, these athletes will compete in more than 500 sporting competitions around the world. The men's pro-cycling team will compete in races such as the USA Pro Cycling Challenge, the Tour of Britain and the Paris-Tours, with the ultimate goal of joining the Tour de France.

"As part of our long-standing Changing Diabetes® programme, this partnership provides a tremendous opportunity to raise awareness, and educate, empower and inspire people with diabetes," says Jakob Riis, senior vice president, Global Marketing and Global Medical Affairs, Novo Nordisk. "This is yet another way Novo Nordisk is striving to create more opportunities to live well with diabetes."

Phil Southerland founded what was known as 'Team Type 1' in 2005 and included riders and athletes with and without diabetes until this year. The new Team Novo Nordisk will only comprise of athletes who have diabetes and will continue to grow the team mission "to instil hope and inspiration for people around the world affected by diabetes."

"As Team Novo Nordisk we want to show the world what is possible with great diabetes control. Between us, Team Novo Nordisk has over 1,000 diagnosed years of diabetes with no complications and we stand for what life with diabetes can be like," Southerland says. "Exercise is that billion dollar drug that nobody ever gets prescribed, and in my experience is the best of them all. With appropriate diet, exercise, treatment and technology, anyone with diabetes can achieve their dreams."

About Diabetes
Today, 371 million people are living with diabetes.(1) Changing Diabetes® is Novo Nordisk's global commitment to improve conditions for the millions of people who live with diabetes around the world today, and those who are at risk of developing diabetes tomorrow. It is a global advocacy and partner platform which advocates for the prevention and early detection of diabetes, as well as improved treatment, care and health outcomes.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

1. International Diabetes Federation. IDF Diabetes Atlas, 5th Edition, 2012 Update. Brussels, Belgium: International Diabetes Federation.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...